Epigenetic Remodeling Through GSK343-induced EZH2 Inhibition Alters SMYD2/SMYD3 Expression and Promotes Antitumor Effects.
These findings demonstrate that EZH2 inhibition promotes coordinated epigenetic remodeling and disrupts key oncogenic pathways in breast cancer cells, and suggest potential combinatorial strategies integrating EZH2 inhibition with other targeted or epigenetic therapies to enhance treatment efficacy, overcome resistance...